Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and ...

The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing ...

Insitro has teamed up with Eli Lilly to help power programs into the clinic, tapping the Big Pharma for an option on ...

In a departure from most deals, startup insitro will in-license Lilly’s delivery technology for its investigational ...

Insitro has signed three strategic agreements with Eli Lilly aimed at advancing treatments for metabolic diseases like MASLD, ...

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic ...

KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated ...

Prime Medicine's layoffs are part of a pattern. At least a half-dozen gene-editing companies have laid off staff in the past ...

Take a closer look at 12 biotech unicorns, with a worth of more than $1 billion, that are trying to revolutionize the ...

If all goes according to plan, insitro could finally start testing its first drug in clinical trials in 2026, eight years ...

That includes Recursion – which made $436 million from its IPO – while Insitro and Insilico Medicine have made $400 million and $255 million, respectively, from their third rounds.

Companies to extend collaboration on DACRAs with an additional collaboration molecule and investigation of the DACRA platform within multiple indications LUGANO, Switzerland, Oct. 10, 2024 ...